Pharmacyclics’ Xcytrin Gets FDA “Not Approvable” For NSCLC Patients With Brain Metastases
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Richard Miller calls for FDA to release the “biotech bottleneck” caused by its approvals process.
You may also be interested in...
FDA Panel Views On PFS Endpoint For Avastin Could Impact Fate Of Other First-Line Cancer Drugs
Panel’s rejection of Genentech sBLA for first-line breast cancer despite meeting endpoint of progression-free survival leaves Wall Street wondering if same fate will befall ImClone/Bristol’s Erbitux in colon cancer.
Pharmacyclics Taps Little-Used Regulatory Pathway For Xcytrin NDA
Firm’s decision to “file over protest” asks FDA to review NDA that received “refuse to file” letter in February.
Pharmacyclics Gets “Refuse To File” Letter On Xcytrin
Company had hoped for priority review when it submitted its NDA for treatment of brain metastases from non-small cell lung cancer in December.